Technology in Anesthesiology

Shockwave Medical, Inc., part of Johnson & Johnson MedTech, announced the full U.S. launch of the Shockwave E⁸ Peripheral IVL Catheter, following clearance by the FDA. The Shockwave E⁸ catheter is designed to optimize the treatment of patients with calcified femoro-popliteal and below-the-knee peripheral artery disease (PAD), including patients with complex chronic limb-threatening ischemia (CLTI).

PAD affects more than eight million people aged 40 and older in the United States, increasing risk of heart attack or stroke. CLTI is the most advanced and serious form of PAD and is associated with 40% major amputations at one year, and a 50% mortality rate at five years, worse than most forms of cancer.

With 400 pulses delivered twice per second, and eight emitters across an 80mm balloon, Shockwave E⁸ can treat longer lesions more efficiently. With an increased catheter working length of 150cm, physicians can extend their IVL treatment to reach below-the-knee and very distal lesions. Combined with Shockwave L⁶, Shockwave M⁵⁺, and Shockwave S⁴ IVL catheters, the addition of Shockwave E⁸ offers physicians a complete IVL portfolio to treat challenging calcified lesions across the entire peripheral anatomy.

Source: asamonitor.pub/4eVvwsH